Semaglutide

Semaglutide (5 mg) provides a larger research quantity of this potent long-acting GLP-1 receptor agonist for extended experimental protocols, dose-response studies, and comprehensive metabolic research. Its extended half-life (~168 hours) and high receptor affinity make it the gold standard compound for incretin-based metabolic research. The 5 mg format supports multi-week chronic administration studies, multi-endpoint metabolic investigations, and pharmacokinetic profiling experiments. Current research frontiers include investigation of semaglutide's effects on cardiovascular inflammation (via CRP and IL-6 reduction), hepatic steatosis resolution, addictive behavior modulation through reward circuit GLP-1R activation, and its potential neuroprotective effects in neurodegenerative disease models. The larger quantity also facilitates comparative studies against other GLP-1 agonists and multi-receptor agonist compounds.